Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2007; 49:1459-1464, doi:10.1016/j.jacc.2007.01.027 (Published online 20 March 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van der Harst, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by van der Harst, P.

Telomere Length of Circulating Leukocytes Is Decreased in Patients With Chronic Heart Failure

Pim van der Harst, MD, PhD*,{dagger}, Gerrit van der Steege, PhD{ddagger}, Rudolf A. de Boer, MD, PhD*, Adriaan A. Voors, MD, PhD*,*, Alistair S. Hall, MD, PhD§, Marcel J. Mulder{ddagger}, Wiek H. van Gilst, PhD{dagger}, Dirk J. van Veldhuisen, MD, PhD, FACC* on behalf of the MERIT-HF Study Group

* Department of Cardiology
{dagger} Department of Clinical Pharmacology
{ddagger} Medical Biomics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
§ British Heart Foundation Research Center, University of Leeds, Leeds, United Kingdom.


Figure 1
View larger version (31K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 1 Telomere Length in Control Patients and CHF Patients

Telomere length, expressed as the natural log (Ln) of the telomere to single reference gene (T/S) ratio, is plotted as a function of age. The median telomere length was 0.64 (interquartile range [IQR] 0.47 to 0.88) in chronic heart failure (CHF) patients compared with 1.05 (IQR 0.86 to 1.29) in control patients (p < 0.001). Yearly decline of telomere length ratio was 0.0079 ± 0.0022 in CHF patients and 0.0077 ± 0.0026 in control patients (p = NS). Linear regression line and mean 95% confidence interval lines are drawn for CHF patients and control patients. Solid squares = controls; open circles = CHF.

 

Figure 2
View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 2 Relationship Between Severity and Etiology of CHF With Telomere Length

Median and interquartile range (box) of telomere length (A) of CHF patients according to the severity of the disease measured by New York Heart Association functional classification; telomere length is incrementally shortened with increased New York Heart Association functional class (p < 0.05 for trend). (B) Patients with CHF have decreased telomere length compared with healthy control patients (p < 0.001). The CHF patients with concomitant coronary artery disease (CAD) have further decreased telomere length (p < 0.05). Abbreviations as in Figure 1.

 

Figure 3
View larger version (32K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 3 Number of Atherosclerotic Disease Manifestations and Telomere Length in CHF Patients

Median and interquartile range (box) of telomere length of CHF patients is gradually decreased according to the number of atherosclerotic disease manifestations: none, 1 (coronary, cerebrovascular, peripheral), 2 (any combination of the previous), or 3. Abbreviations as in Figure 1.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement